Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity - Schellekens - 2004 - European Journal of Clinical Investigation - Wiley Online Library
EMJ Oncology 6 [Suppl 2] 2018 - European Medical Journal
Efficacy and Safety of Orally/Sublingually, Intranasally, and Intraperitoneally Administered Recombinant Murine Interferon in th
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
Clinical comparability and European biosimilar regulations
Professor Schellekens maakt medicijnen zelf - Zembla - BNNVARA
Opgestapt CBG-lid Huub Schellekens uit forse kritiek op 'de perversies van het systeem' - Human - VPRO
Cv huub schellekens complet by Ricardo Guerrero - Issuu
The First Biosimilar Epoetin: But How Similar Is It?
eLearning module: Clinical development – Biosimilars: From concern to confidence
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Huub Schellekens – Studium Generale Universiteit Utrecht
Development of <fc>ADA</fc> Against Recombinant Human Interferon Beta in Immune Tolerant Mice Requires Rapid Recruit
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
Immunogenicity: The key issue for multisource biologics
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
Huub Schellekens | European Association of Hospital Pharmacists
Development of a Transgenic Mouse Model to Study the Immunogenicity of Recombinant Human Insulin
Biosimilar therapeutics—what do we need to consider?
Schellekens, Huub | European Association of Hospital Pharmacists
Personalised medicine produced in a “Bionexpresso” - News - Utrecht University
Huub Schellekens – Studium Generale Universiteit Utrecht
